NCT Number: NCT03080298
Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire
This is study of the efficacy, safety and pharmacokinetics of BP101 compared to placebo in patients with a decrease or loss of sexual desire.
Looking for future studies?
Notify MeKey information
Conditions
Age range
21 year and older
Sex eligibility
Female
Study type
Interventional
Phase
Phase 2
Primary location
V.M. Bekhterev Republic Clinical Psychiatric Hospital, Kazan', Russia
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Women aged 21 or older, who have signed informed concent, with a regular menstrual cycle (STRAW stages -5 to -3 (see Annex 7)).
- The level of follicle-stimulating hormone (FSH) is not more than 25 milli-International unit per ml (mIU/ml) according to the screening values.
- Decrease or loss of sexual desire (ICD-10 code: F-52.0) corresponding to the hypoactive sexual desire disorder (HSDD) diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM4), criteria.
- Current HSDD episode lasting not less than 24 weeks.
- Patients with secondary female sexual arousal disorder (FSAD) and/or female orgasmic disorder (FOD) will be eligible only if the HSDD developed before the FSAD and/or FOD and the HSDD has a more significant impact on the patient's quality of life.
- Not less than 15 scores according to the FSDS-R (Distress) Total Score.
- Stable monogamous relationship with one sexually active male sexual partner lasting at least a year. The partner is physically available not less than 50% of time during a month.
- Consent to attempt to have a sexual intercourse at least twice a month, if she has a desire.
- Consent to complete a diary every day during the screening period and assessment of the baseline state (in this period diary records must cover ≥80% days), during the therapy and subsequent follow-up.
- Consent to use adequate methods of contraception throughout the study.
Exclusion criteria
- Any prohibited treatments.
- Other mental disorders or psychiatric diseases.
- Score ≥ 20 according to the Beck Depression Inventory during the screening. Patients with 16 to 19 scores according to Beck's inventory may be included in the study unless, in the investigator's opinion, an actual depressive disorder is observed in the patient.
- Inflammatory diseases of pelvic organs, infections of the genitourinary system, cervicitis, interstitial cystitis, vulvodynia or severe atrophy of the vaginal epithelium.
- Surgical interventions (other than cosmetic surgeries) on reproductive organs in past medical history (ovariectomy, hysterectomy, obvious scars from childbirth-related perineal stitches, etc).
- Pregnant and nursing women or non-lactating women during the first 12 months after childbirth.
- Consumption of more than 5 portions of alcoholic drinks per week or alcohol addiction, drug addiction or drug abuse in the past. One portion of an alcoholic drink means 360 ml of beer, 120 ml of wine or 30 ml of a strong alcoholic drink.
Treatment and study plan
Placebo
DrugPrimary outcomes
-
Desire domain score in the Female Sexual Function Index
Time frame: 28 days (4 weeks) of treatment
Change in the Desire domain score in the Female Sexual Function Index (FSFI) after 28 days (4 weeks) of treatment compared with the baseline.
-
Item 13 score in the Female Sexual Distress Scale-Revised
Time frame: 28 days (4 weeks) of treatment
Change of Item 13 score in the Female Sexual Distress Scale-Revised (FSDS-R) after 28 days (4 weeks) of treatment compared with the baseline.
Secondary outcomes
-
Desire domain in the Female Sexual Function Index
Time frame: 28 days (4 weeks) of treatment and 56 days (8 weeks) of follow-up
Change of the Desire domain in the Female Sexual Function Index (FSFI) after 28 days (4 weeks) and 56 days (8 weeks) of follow-up compared with the baseline.
-
Item 13 score in the Female Sexual Distress Scale-Revised
Time frame: 28 days (4 weeks) of treatment and 56 days (8 weeks) of follow-up
Change of Item 13 score in the Female Sexual Distress Scale-Revised (FSDS-R) after 28 days (4 weeks) and 56 days (8 weeks) of follow-up compared with the baseline.
-
Satisfying sexual events
Time frame: 28 days (4 weeks) of treatment and 56 days (8 weeks) of follow-up
Change in the number of satisfying sexual events (SSEs) in proportion to the 28 day period after 28 days (4 weeks) of the therapy and after 28 days (4 weeks) and 56 days (8 weeks) of follow-up compared with the baseline.
-
The total score of the Female Sexual Function Index
Time frame: 28 days (4 weeks) of treatment and 56 days (8 weeks) of follow-up
Change of the total score of the Female Sexual Function Index (FSFI) after 28 days (4 weeks) of the therapy and after 28 days (4 weeks) and 56 days (8 weeks) of follow-up compared with the baseline.
-
The total score of the Female Sexual Distress Scale-Revised
Time frame: 28 days (4 weeks) of treatment and 56 days (8 weeks) of follow-up
Change of total score of the Female Sexual Distress Scale-Revised (FSDS-R) after 28 days (4 weeks) of the therapy and after 28 days (4 weeks) and 56 days (8 weeks) of follow-up compared with the baseline.
-
The sexual function according to the Female Sexual Function questionnaire
Time frame: 28 days (4 weeks) of treatment and 56 days (8 weeks) of follow-up
Change of the sexual function according to the Female Sexual Function questionnaire (FSF) after 28 days (4 weeks) of the therapy and after 28 days (4 weeks) and 56 days (8 weeks) of follow-up compared with the baseline.
-
The patient's assessment of efficacy of the therapy according to the Patient Global Impression of Improvement
Time frame: 28 days (4 weeks) of treatment and 56 days (8 weeks) of follow-up
The patient's assessment of efficacy of the therapy according to the Patient Global Impression of Improvement (PGI-I) after 28 days (4 weeks) of the therapy and after 28 days (4 weeks) and 56 days (8 weeks) of the follow-up.
-
Number of adverse events
Time frame: 28 days (4 weeks) of treatment and 56 days (8 weeks) of follow-up
Frequency of adverse events reporting, including serious adverse events, in treatment groups.
Sponsors and collaborators
Lead sponsor
Ivix LLX
Industry
Registry information
Official study title
International, Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2a Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire
Important dates
- Study start
- 2016
- Primary completion
- 2017
- Study completion
- 2017
- First posted
- Mar 15, 2017
- Registry last updated
- Aug 18, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Stress Hormones, Mood and Women's Sexual Desire (MODEST)
NCT01702818
Hypoactive Sexual Desire Disorder (HSDD), Mental Disorders
Vancouver, British Columbia, Canada
View Trial DetailsAcupuncture for Sexual Dysfunction
NCT02070029
Female Sexual Dysfunction (FSD), Hypoactive Sexual Desire Disorder (HSDD)
Cincinnati, Ohio, United States
View Trial DetailsStudy to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
NCT00349791
Hypoactive Sexual Desire Disorder (HSDD), Mental Disorders
Chicago, Illinois, United States
View Trial DetailsThe Impact of Mindful Compassion on Sexual Functioning and Quality of Life in Home Hospice Care
NCT07296796
Behavior, Death
London, United Kingdom
View Trial Details